SS
BLRX

SBI Securities’s BioLineRX BLRX Stock Holding History

SBI Securities’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31 Buy
+10
New +$29 ﹤0.01% 3766
2025
Q4 		– Sell
-2
Closed -$8 – 4044
2025
Q3 		$8 Hold
2
– – ﹤0.01% 4059
2025
Q2 		$9 Hold
2
– – ﹤0.01% 4019
2025
Q1 		$6 Sell
2
-76
-97% -$306 ﹤0.01% 4011
2024
Q4 		$664 Buy
+78
New +$1.15K ﹤0.01% 2790

Other funds holding BLRX

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
BCV
Banque Cantonale Vaudoise Lausanne, Switzerland $722M AUM 30.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

SBI Securities's BLRX Position: Q2 2026 in Review

SBI Securities opened a new position in BioLineRX (BLRX) in Q2 2026: 10 shares worth $31. The stake represents ﹤0.01% of the portfolio and ranks #3766 among its holdings. This is a return to the name: SBI Securities previously reported a position in BLRX as recently as Q3 2025.

SBI Securities first reported a position in BLRX in Q4 2024 and has held it in 5 quarters since. The position peaked at $664 in Q4 2024. 9 funds tracked by Wall St. Rank hold BLRX as of Q2 2026.

  • SBI Securities held 10 shares of BioLineRX worth $31 as of Q2 2026.
  • BioLineRX was a new SBI Securities position in Q2 2026.
  • BioLineRX made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3766 holding.
  • SBI Securities first reported a position in BioLineRX in Q4 2024 and has held it in 5 quarters since.
  • SBI Securities's BioLineRX position peaked at $664 in Q4 2024.
  • 9 funds tracked by Wall St. Rank held BioLineRX as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.